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Abstract  24 
Objectives 25 
Coagulation abnormalities are associated with Puumala virus-induced hemorrhagic fever with renal 26 
syndrome (PUUV-HFRS). We evaluated the coagulation capacity of plasma during acute PUUV-HFRS by 27 
measuring thrombin generation using calibrated automated thrombography (CAT®).  28 
Material and Methods 29 
The study cohort comprised of 27 prospectively collected, consecutive, hospital-treated patients with acute 30 
PUUV infection. Blood samples were drawn in the acute phase and at the control visit approximately 5 31 
weeks later. To evaluate thrombin generation, the lag time of initiation, endogenous thrombin potential 32 
(ETP), and peak and time to peak thrombin concentration were assessed by CAT® in platelet poor plasma 33 
without corn trypsin inhibitor. Plasma levels of D-dimer, fibrinogen and prothrombin fragments (F1+2) were 34 
also evaluated. 35 
Results  36 
When the acute phase was compared with the control phase, ETP was decreased (median 1154 nM/min, 37 
range 67-1785 vs. median 1385 nM/min, range 670-1970; p<0.001), while the lag time was prolonged 38 
(median 3.8 minutes, range 2.1-7.7 vs. median 2.9 minutes, range 2.0-4.1; p<0.001). Low ETP correlated 39 
with low peak thrombin concentration (r=0.833, p<0.001). Prolonged time to peak associated with the lag 40 
time (r=0.78, p<0.001). ETP was associated with thrombocytopenia (r=0.472, p=0.015) and weakly with 41 
fibrinogen level (r=0.386, p=0.047). The measured CAT® parameters did not associate with D-dimer and 42 
F1+2 levels. 43 
Conclusions 44 
Decreased ETP together with low peak and prolonged lag time indicate decreased plasma potential for 45 
thrombin generation in vitro. Together with low platelet count and enhanced fibrinolysis this further refers to 46 
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Hantaviruses are the cause of two disease entities, hemorrhagic fever with renal syndrome (HFRS) in Europe 58 
and Asia, and hantavirus cardiopulmonary syndrome (HCPS) in North and South America. Puumala 59 
hantavirus (PUUV) causes mild HFRS, also called nephropathia epidemica in Europe [1, 2]. PUUV-HFRS is 60 
characterized by thrombocytopenia and coagulation abnormalities, acute kidney injury and capillary leakage 61 
[1-3]. Petechiae, epistaxis, hematuria and conjunctival bleedings are common [1]. Hemorrhagic gastropathy 62 
is observed in all PUUV-HFRS patients in gastroscopy [4]. Severe and fatal hemorrhages of pituitary gland, 63 
kidneys, heart, liver, lungs and peritoneal cavity have been described [5, 6]. The risk for cardiovascular 64 
disease has also been linked with PUUV-HFRS [7]. Disseminated intravascular coagulation has been 65 
encountered in severe cases [8, 9]. 66 
Hantaviruses target vascular endothelial cells via ß3 integrin receptor and adhere quiescent platelets to the 67 
endothelium, thus contributing to vascular permeability and thrombocytopenia [10]. Through interactions 68 
with hantavirus, platelets and endothelium, alterations in the coagulation system occur. Previous studies 69 
imply enhanced thrombin formation, as evaluated by shortened prothrombin time (PT) and thrombin time 70 
(TT), and overall increase in prothrombin fragments 1+2 (F1+2), and decreased levels of natural 71 
anticoagulants, antithrombin (AT), protein C (PC) and protein S free antigen (PS) [8, 11]. A study with 72 
PUUV infected human umbilical vein endothelial cells suggests increased tissue factor (TF) activity [12]. 73 
Fibrinolysis is activated as indicated by increased concentrations of fibrin degradation products, D-dimer and 74 
tissue plasminogen activator (tPA) [8, 13]. Platelet ligands are altered, and ADAMTS13 activity is decreased 75 
[14].  76 
Thrombin is the key enzyme during coagulation leading to the conversion of fibrinogen to fibrin and clot 77 
formation. Thrombin generation (TG) assays are useful indicators of the overall plasma coagulability, in 78 
contrast to the conventional coagulation tests that mainly assess individual factors or a part of the 79 
coagulation pathway. Calibrated automated thrombography (CAT®) measures in vitro TG of plasma by 80 
continuous cleavage of a fluorogenic substrate, thus expressing the overall haemostatic potential [15]. CAT® 81 
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is applied in research of vascular thrombosis, bleeding disorders and monitoring of anticoagulant treatment 82 
[16]. To our knowledge, studies on TG by CAT® in hantavirus infections are yet lacking. 83 
Both hemorrhagic and thrombotic events have been associated with PUUV-HFRS, but the underlying 84 
mechanisms of alterations in coagulation system are not well defined. Therefore, we aimed to evaluate the 85 
plasma coagulation capacity in PUUV-infected patients by measuring TG by CAT®. The goal was to 86 
describe how TG is altered during the acute phase of infection, and further determine the possible hypo- or 87 
hypercoagulability associated with hantavirus infection. We also sought to investigate the possible 88 
associations of CAT® assay with the tests applied to measure thrombin formation and fibrinolysis in clinical 89 
practice and variables depicting disease severity of acute PUUV-HFRS.  90 
Material and Methods 91 
Ethics statement 92 
All patients were recruited and enrolled after providing a written informed consent. The study protocol was 93 
approved by the Ethics Committee of Tampere University Hospital. The study was conducted according to 94 
the principles expressed in the Declaration of Helsinki. 95 
Patients 96 
The study was carried out in Tampere University Hospital, University of Tampere, Helsinki University 97 
Hospital and University of Helsinki. All patients came from the Pirkanmaa area and were hospitalized at 98 
Tampere University Hospital due to serologically confirmed acute PUUV-HFRS [17] during the period from 99 
October 2010 to February 2014. 100 
Twenty-seven prospectively collected, consecutive patients (17 males) with acute PUUV-HFRS were 101 
included. Their median age was 50 years (range 21-67 years). None of the subjects used anticoagulant or 102 
immunosuppressive therapy. Two patients used an anti-platelet drug (acetylsalicylic acid). 103 
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Clinical and laboratory data 104 
The following variables were recorded: the number of days from the onset of fever before the acute-phase 105 
study samples were collected, the length of hospital stay (days), signs of bleeding symptoms (yes/no), 106 
thromboembolic complications (yes/no), need for transient hemodialysis treatment (yes/no), and maximum 107 
gain in weight (kg). Complete blood count, plasma C-reactive protein (CRP) and plasma creatinine were 108 
measured according to clinical need. The laboratory analyses were carried out at the Laboratory Centre of 109 
Pirkanmaa Hospital District using standard methods. 110 
Methods 111 
The study design was longitudinal with two time-points of blood draw for CAT®. The acute phase samples 112 
(n=27) were taken median 7 days (range 4-12 days) from the onset of fever. Control samples (n=23) were 113 
taken at the follow-up visit, median 43 days (range 38-76 days) from the onset of fever. The blood count was 114 
assessed in the acute and control phase of CAT® study days, and the lowest platelet count during the 115 
hospital stay was recorded. 116 
CAT® analyses and plasma measurements of fibrinogen, F1+2 and D-dimer were carried out in Clinical 117 
Chemistry coagulation laboratory (HUSLAB Laboratory Services, Helsinki University Central Hospital, 118 
Finland). D-dimer (Tina Quant D-Dimer®, Roche Diagnostics, Mannheim, Germany) and fibrinogen 119 
(Multifibren U® Siemens Healthcare Diagnostics) levels were determined according to manufacturer’s 120 
recommendations. F1+2 were measured by an enzyme immunoassay (Enzygnost® F1+2, monoclonal, 121 
Siemens Healthcare Diagnostics). The reference values for D-dimer were ≤ 0.5 mg/l, fibrinogen 1.7-4.0 g/l 122 
and F1+2 69-229 pmol/l. 123 
Measurement of thrombin generation by CAT® 124 
TG was measured using CAT® (Diagnostica Stago) with the Stago PPP reagent (tissue factor 5 pM and 125 
phospholipids 4 μM) without corn-trypsin inhibitor. The lag time of the initiation of TG (LT, min), the 126 
endogenous thrombin potential (ETP; the area under the curve; nM thrombin x time), peak (maximum 127 
thrombin concentration, nM) and time to peak (tt Peak, min) were measured and recorded according to the 128 
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manufacturer's instructions. Blood samples were collected into sodium citrate anticoagulant (3.2%; 109 mM) 129 
tubes according to the local sampling protocol as part of hospital routine, and centrifuged (at 2500 g for 15 130 
min). The PPP was separated within 2 hours and stored at -80 °C before analysis. 131 
Statistics 132 
All continuous, skewed variables were determined as medians and ranges. The associations between TG 133 
markers and clinical and laboratory variables were evaluated for continuous data by Spearman rank 134 
correlation coefficient. To analyze the changes between the acute and control phase, Wilcoxon-signed rank 135 
test was used for pairwise comparisons. The level of significance was set at p value 0.05 (2-tailed). Statistical 136 
analyses were performed with IBM SPSS Statistics for Windows version 22.0 (Armonk, NY, USA). 137 
Results 138 
Clinical and laboratory findings 139 
All 27 patients suffered from clinically typical and serologically confirmed PUUV-HFRS [17]. The clinical 140 
and laboratory findings of the patients are shown in Table 1. Mild bleedings were reported in eight patients 141 
including nasal and conjunctival hemorrhages, petechiae, hemoptysis and melena. There were no 142 
thromboembolic events recorded. None of the patients needed transient hemodialysis treatment. 143 
The acute phase median platelet count was 68 x 109/l (range 8-222 x 109/l), CRP 57 mg/ml (10-178 mg/ml), 144 
hemoglobin 139 g/l (120-177 g/l), hematocrit 0.40 (0.34-0.49) and creatinine 126 µmol/l (52-699 µmol/l). 145 
Twenty-four out of 27 patients were thrombocytopenic (lowest platelet count <150 x 10⁹/l). 146 
 Thrombin generation by CAT® 147 
When compared with the control phase, ETP was diminished by 16% (1154 nM/min, 67-1785 nM/min vs. 148 
1385 nM/min, 670-1970 nM/min; p<0.001). Additionally, tt peak was prolonged (7.3 minutes, 4.8-14.9 149 
minutes vs. 5.9 minutes, 4.3-9.8 minutes; p=0.012). Peak thrombin concentration was lowered (204 nM, 5.6-150 
293 nM vs. 243 nM, 106-331 nM; p=0.008), and LT was prolonged (3.8 minutes, 2.1-7.7 minutes vs. 2.9 151 
minutes, 2.0-4.1 minutes; p<0.001) in the acute phase. Accordingly, ETP correlated with peak thrombin 152 
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concentration (r=0.833, p<0.001; Fig. 1A). Tt peak associated with the LT (r=0.78, p<0.001; Fig. 1B). An 153 
inverse correlation was observed between peak and tt peak (r= -0.54, p=0.004).  154 
Associations of CAT® parameters with variables depicting clinical disease 155 
In the acute phase, ETP associated with the platelet count measured in the CAT® study day sample (r=0.472, 156 
p=0.015; Fig. 1C), and with the lowest platelet count measured during the hospital stay (r=0.402, p=0.038). 157 
Similarly, peak thrombin concentration associated with the platelet count of the CAT® study day (r=0.554, 158 
p=0.003), and with the lowest platelet count measured during the hospital stay (r=0.462, p=0.015). Prolonged 159 
LT and low ETP associated with increased fibrinogen level measured in the acute phase (r=0.511, p=0.006 160 
and r=0.386, p=0.047, respectively; Fig. 1D). The fibrinogen level was acutely increased compared with the 161 
control phase (median 4.2, range 2.2-9.6 g/l and median 3.4 g/l, range 2.6-4.9 g/l, respectively; p=0.005).  162 
D-dimer was increased in the acute phase (2.8 mg/l, 0.6-34 mg/l vs. 0.4 mg/l, 0.2-1.1 mg/l; p<0.001). 163 
D-dimer associated strongly with F1+2 (r=0.843, p<0.001). F1+2 was increased acutely (704 pmol/l, 284-164 
1875 pmol/l vs. 263 pmol/l, 118-556 pmol/l; p<0.001). ETP did not associate with D-dimer and F1+2 165 
(r=-0.079, p=0.695 and r=-0.164, p=0.415, respectively). There were no associations between peak and D-166 
dimer and F1+2 (r=-0.030, p=0.882 and r=-0.162, p=0.418, respectively).  167 
Clinical variables depicting the disease severity, i.e. maximum leukocyte count, maximum plasma creatinine, 168 
CRP level and length of hospital stay were not associated with CAT® parameters (data not shown). 169 
Furthermore, reduced ETP was not associated with bleedings (data not shown). 170 
Discussion 171 
The primary aim of this study was to investigate whether thrombin generation (TG), measured using 172 
calibrated automated thrombography (CAT®) assay, is altered during acute Puumala virus -induced 173 
hemorrhagic fever with renal syndrome (PUUV-HFRS). In addition, we sought to elucidate the underlying 174 
coagulation mechanisms predisposing to bleeding and thrombosis. The main findings were reduced 175 
endogenous thrombin potential (ETP) and peak thrombin concentration suggesting diminished plasma 176 
potential for TG during acute PUUV-HFRS. Prolonged lag time (LT) indicating slower initiation of burst, 177 
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and extended time to reach the peak representing the velocity of TG, further support the finding of 178 
hypocoagulability. Decreased platelet count, one of the clinical characteristics of hantavirus infection, was 179 
found to associate with low ETP and low peak thrombin concentration. We did not find statistically 180 
significant associations between prothrombin fragments F1+2 (F1+2), D-dimer and CAT® parameters in this 181 
study population.  182 
Previous studies imply enhanced TG in acute PUUV-HFRS on the basis of increased prothrombin fragments 183 
F1+2 generated during conversion of prothrombin to thrombin, and an increased level of fibrin degradation 184 
product D-dimer [8, 9, 11]. High levels of circulating F1+2 and D-dimer observed in this study confirm 185 
previous findings. In vivo TG parameters, F1+2 and D-dimer, strongly depend on the amount of tissue factor 186 
(TF) and thrombomodulin present on vascular endothelial cells [16, 18]. In vivo TG is also ongoing in the 187 
microparticles released during infection [19, 20]. Data suggests increased TF in endothelial cells in the acute 188 
phase of PUUV-HFRS [12]. On the other hand, the in vitro thrombin potential assessed by CAT® 189 
determines how thrombin can be generated by plasma containing a defined amount of TG trigger. Thus, it 190 
measures the haemostatic balance of plasma clotting factors and inhibitors independently of the procoagulant 191 
and inhibitory drivers released by the endothelium [18]. The difference between in vivo and in vitro TG is 192 
well reflected in consumption coagulopathy, a condition where indicators of ongoing coagulation are 193 
increased, but plasma potential of TG is decreased [21].  194 
A previous study indicates slightly prolonged prothrombin time (PT), prolonged activated partial 195 
thromboplastin time (APTT), and shortened thrombin time (TT) during acute PUUV-HFRS [8, 18]. These in 196 
vitro coagulation tests cannot detect the in vivo contribution of endothelial cells and shear stress of blood 197 
flow on local clot formation and fibrinolysis. Traditional coagulation tests APTT and PT assess the time to 198 
the initiation of clot formation and thus they do not entirely reflect the hemostatic balance in acutely ill 199 
patients [22]. These plasma clotting assays are considered to reflect the LT phase of TG in CAT® assay [22]. 200 
Our observation of prolonged LT indicating slower initiation of TG is in line with the previous findings of 201 
the coagulation tests APTT and PT. As the data concerning in vitro coagulation tests is lacking in the current 202 
study population, the direct comparison with CAT® parameters is not possible. 203 
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Fibrinolysis is increased, as indicated by high D-dimer and endothelial cell tissue plasminogen activator 204 
(tPA) levels, during PUUV infection [8, 11-13]. The plasminogen activator inhibitor 1 (PAI-1) level is not 205 
altered in the acute phase [13]. Thrombomodulin-associated thrombin activates the thrombin activatable 206 
fibrinolysis inhibitor (TAFI), which downregulates fibrinolysis. It can be speculated that low ETP may 207 
contribute to decreased TAFI and thus increased fibrinolysis and bleeding tendency [23]. Diminished TG in 208 
PUUV-HFRS together with excessive fibrinolysis also resembles the data obtained in another hemorrhagic 209 
fever, dengue virus infection [24, 25]. In dengue fever the bleeding complications have been shown to 210 
associate with reduced thrombin formation along with thrombocytopenia and enhanced fibrinolysis [26]. We 211 
did not find an association between low ETP and bleedings, although mild bleedings were reported in one 212 
third of the patients.  213 
We are aware of the relatively small sample size of the study. Yet, the associations were statistically 214 
significant, even if the number of clinical events remained minor. The levels of coagulation factors were not 215 
available and individual acquired or inherited factors affecting hemostasis could not be assessed. Two 216 
patients used aspirin, a platelet antagonist that inhibits platelet aggregation and thrombin formation. As TG 217 
was assessed in platelet poor plasma it is unlikely that aspirin, attached to the minor amount of residual 218 
platelets, could affect these CAT® results.  219 
Ongoing in vivo coagulation may result in consumption of platelets and coagulation factors during acute 220 
PUUV-infection. Correlation of low platelet count with low ETP and low peak may imply thrombin 221 
activation and consumption of platelets, as thrombopoiesis is shown to be active during acute PUUV-HFRS 222 
[20]. Natural anticoagulants, protein C and protein S free antigen and antithrombin are also found to be 223 
decreased in the acute phase of PUUV-HFRS [8]. Increased TF expression on the endothelial cells and 224 
microparticle release might result in consumption of platelets and clotting factors resulting in lower ETP. All 225 
of these findings are supported by the previous reports [8, 11, 20]. 226 
In conclusion, in this study we found decreased in vitro TG measured by CAT® in acute PUUV infection. 227 
Together with thrombocytopenia, increased fibrinolysis and signs of enhanced TG in vivo this data suggests 228 
a mild to moderate consumption coagulopathy during acute PUUV-HFRS. The CAT® results of plasma 229 
11 
 
hypocoagulobility support previous findings of impaired hemostasis during acute PUUV-HFRS. Larger 230 
future studies might further clarify the role of coagulation in the pathogenesis of HFRS.  231 
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Figure Legend 300 
 301 
Figure 1. Scatter plots illustrating the correlation between endogenous thrombin potential and peak thrombin 302 
concentration (Fig.1A), lag time and time to peak thrombin concentration (Fig. 1B), endogenous thrombin 303 
potential and simultaneous platelet count (Fig. 1C) and endogenous thrombin potential and plasma 304 
fibrinogen level (Fig. 1D) during acute PUUV infection. 305 
 306 
Figure Click here to download Figure Figure_1.tif 
  
Table 1. The clinical and laboratory findings during hospital care in 27 patients with acute Puumala 
hantavirus infection. 
 
Clinical or laboratory variable Median Range 
 
Days from the onset of illnessa 7 4-12 
Length of hospital stay (days) 7 3-12 
Body mass index (kg/m2) 26.6 22.3-36.8 
Change in weight (kg)b 3.8 0.5-11.3 
Systolic BP min (mmHg) 108 80-135 
Diastolic BP min (mmHg) 67 55-83 
Creatinine max (µmol/l) 268 71-983 
Leukocyte count max (x 109/l) 10.7 4-45 
Hemoglobin max (g/l) 155 122-214 
Hematocrit max  0.43 0.37-0.60 
Platelet count min (x 109/l) 60 5-150 
CRP max (mg/ml) 79 21-244 
 
Abbreviations: min=minimum, max=maximum, BP=blood pressure. 
Reference values: hematocrit 0.35-0.50 for men and 0.35-0.46 for women, platelet count 150-360, leukocyte 
count 3.4-8.2 x 109/l, CRP < 10 mg/ml, creatinine < 105 µmol/l for men and < 95 µmol/l for women. 
a The number of days of fever before the first study samples were obtained. 
b Reflects fluid accumulation in the oliguric phase of PUUV-HFRS. 
Table
